Pediatric Rheumatology Symposium
About the Event
Date:2026 | To Be Announced
Location:To Be Announced
Credit:CME: TBA, ABIM & ABP MOC: TBA
On Demand:To Be Announced
The Pediatric Rheumatology Symposium (PRSYM) will provide up-to-date, practical clinical information and basic science knowledge on the diagnosis and management of pediatric patients with rheumatic diseases and immune disorders.
Key opinion leaders will deliver a range of content in areas such as therapeutic developments, recent research findings, and scientific advances, in an environment conducive to dialogue and networking.
Target Audience
Rheumatologists, physicians and other healthcare providers who care for pediatric patients with rheumatic diseases, clinical investigators, physician-scientists and those interested or engaged in research in the field of pediatric rheumatic diseases.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the most up-to-date clinical information on the diagnosis and management of pediatric patients with rheumatic and immunologic disorders
- Describe the most current information regarding the pathophysiology underlying pediatric rheumatic disorders
See information from the 2023 meeting in the Pediatric Rheumatology Symposium 2023 section below.
Program Schedule & Syllabi
To be announced
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
CME
ACCME Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
AMA Designation Statement
The ACR designates this activity for a maximum of (to be announced) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by (to be announced).
MOC
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to (to be announced) MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC Recognition Statement: American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to (to be announced) MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABP diplomates to the ABP diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABP Physician Portals. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by (to be announced).
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
2026 disclosures to be announced.
View ACR's ACCME disclosure practices
See 2023 disclosures in the 2023 meeting section below.
See key takeaways from your colleagues that attended PRSYM 2023.
CME & MOC Information
CME: 20.75
ABIM & ABP MOC: 20.75
CME credit must be claimed by March 30, 2024 at 11:59 PM ET.
MOC points must be claimed by December 31, 2023 at 11:59 PM ET.
Target Audience
Rheumatologists, physicians and other healthcare providers who care for pediatric patients with rheumatic diseases, clinical investigators, physician-scientists and those interested or engaged in research in the field of pediatric rheumatic diseases.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the most up-to-date clinical information on the diagnosis and management of pediatric patients with rheumatic and immunologic disorders
- Describe the most current information regarding the pathophysiology underlying pediatric rheumatic disorders
Program Schedule & Syllabi
Pediatric Rheumatology Symposium Program Schedule
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
On-Demand
On-demand access for this activity is no longer available.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Abstracts
Accepted Pediatric Rheumatology Symposium 2023 abstracts are available on the ACR abstracts website.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.